[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Climb Bio Inc (CLYM)

Climb Bio Inc (CLYM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 937,930
  • Shares Outstanding, K 57,436
  • Annual Sales, $ 0 K
  • Annual Income, $ -59,850 K
  • EBIT $ -65 M
  • EBITDA $ -67 M
  • 60-Month Beta 0.08
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.52

Options Overview Details

View History
  • Implied Volatility 146.23% (+8.25%)
  • Historical Volatility 68.92%
  • IV Percentile 12%
  • IV Rank 3.17%
  • IV High 728.63% on 02/05/26
  • IV Low 127.18% on 08/12/26
  • Expected Move (DTE 5) 0.71 (4.37%)
  • Put/Call Vol Ratio 3.55
  • Today's Volume 550
  • Volume Avg (30-Day) 331
  • Put/Call OI Ratio 0.23
  • Today's Open Interest 7,062
  • Open Int (30-Day) 5,045
  • Expected Range 15.62 to 17.04

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.21
  • Number of Estimates 7
  • High Estimate $-0.16
  • Low Estimate $-0.30
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) -10.53%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.36 +43.75%
on 08/03/26
17.00 -3.94%
on 08/14/26
+3.09 (+23.34%)
since 07/14/26
3-Month
9.25 +76.54%
on 05/19/26
17.00 -3.94%
on 08/14/26
+5.00 (+44.13%)
since 05/14/26
52-Week
1.54 +960.39%
on 10/07/25
17.00 -3.94%
on 08/14/26
+14.61 (+849.42%)
since 08/14/25

Most Recent Stories

More News
Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

CLYM116 Phase 1 data in healthy volunteers to be presented at R&D Spotlight Event on September 3, 2026 Anticipate CLYM116 Phase 2 trial in IgA nephropathy to initiate dosing in Q3 2026 Budoprutug...

CLYM : 16.33 (+10.86%)
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026

Data demonstrate favorable safety and tolerability profile, robust B - cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment...

CLYM : 16.33 (+10.86%)
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer Initiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected...

CLYM : 16.33 (+10.86%)
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026

WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 16.33 (+10.86%)
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect

Climb Bio (NASDAQ:CLYM) outlined its clinical development strategy and upcoming data readouts during a fireside chat at H.C. Wainwright’s BioConnect Conference, with management emphasizing two biologic...

CLYM : 16.33 (+10.86%)
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress

WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 16.33 (+10.86%)
Climb Bio to Present at Upcoming Investor Conferences

WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 16.33 (+10.86%)
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at...

CLYM : 16.33 (+10.86%)
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast...

CLYM : 16.33 (+10.86%)
Climb Bio, Inc. Announces $110.0 Million Private Placement

WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 16.33 (+10.86%)

Business Summary

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell...

See More

Key Turning Points

3rd Resistance Point 20.23
2nd Resistance Point 18.62
1st Resistance Point 17.47
Last Price 16.33
1st Support Level 14.71
2nd Support Level 13.10
3rd Support Level 11.95

See More

52-Week High 17.00
Last Price 16.33
Fibonacci 61.8% 11.09
Fibonacci 50% 9.27
Fibonacci 38.2% 7.45
52-Week Low 1.54

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.